Covered recipient · General Payments record
ROBERT S BUSCH
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$660,950.66
872 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $455,250.25 | 240 |
| Travel and Lodging | $118,818.82 | 258 |
| Consulting Fee | $65,510.00 | 23 |
| Food and Beverage | $15,174.17 | 327 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $5,700.00 | 3 |
| Education | $497.42 | 21 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $146,891.00 | 252 |
| Janssen Pharmaceuticals, Inc | $107,684.51 | 96 |
| Novo Nordisk Inc | $102,564.38 | 106 |
| Amarin Pharma Inc. | $87,452.71 | 90 |
| SANOFI-AVENTIS U.S. LLC | $38,475.21 | 44 |
| Merck Sharp & Dohme Corporation | $34,910.65 | 38 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $34,077.56 | 53 |
| Amgen Inc. | $28,751.31 | 31 |
| AstraZeneca Pharmaceuticals LP | $24,102.91 | 32 |
| Novo Nordisk AS | $22,893.94 | 19 |
| Abbott Laboratories | $12,706.88 | 22 |
| AbbVie, Inc. | $11,278.14 | 17 |
| Regeneron Healthcare Solutions, Inc. | $3,621.15 | 11 |
| Regeneron Pharmaceuticals, Inc. | $3,474.04 | 8 |
| Eli Lilly and Company | $1,326.51 | 28 |
| Insulet Corporation | $253.03 | 12 |
| Mannkind Corporation | $241.32 | 4 |
| Senseonics, Incorporated | $182.00 | 5 |
| Corcept Therapeutics | $29.21 | 2 |
| Kowa Pharmaceuticals America, Inc. | $20.43 | 1 |
| Dexcom, Inc. | $13.77 | 1 |
Page 4 of 18; records 151–200 of 872 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ROBERT S BUSCH
NPI 1457358715 · CMS profile ID 293095
Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
ALBANY, NY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 18; records 151–200 of 872 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1457358715?year=2019&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ROBERT S BUSCH, NPI 1457358715, CMS profile ID 293095. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 18; records 151–200 of 872 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457358715?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). ROBERT S BUSCH, NPI 1457358715, CMS profile ID 293095. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 18; records 151–200 of 872 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457358715?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- ROBERT S BUSCH, NPI 1457358715, CMS profile ID 293095, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 18; records 151–200 of 872 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1457358715?year=2019&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
872 matching records · $660,950.66 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 872.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $112.24 | 10/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658380243 | CMS |
| Janssen Pharmaceuticals, Inc | $9.83 | 10/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658380247 | CMS |
| Janssen Pharmaceuticals, Inc | $1,243.53 | 10/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658380231 | CMS |
| Janssen Pharmaceuticals, Inc | $125.00 | 10/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658380233 | CMS |
| Lilly USA, LLC | $400.00 | 10/07/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658106123 | CMS |
| Lilly USA, LLC | $1,000.00 | 10/07/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658113007 | CMS |
| Lilly USA, LLC | $500.00 | 10/07/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658123655 | CMS |
| Lilly USA, LLC | $1,600.00 | 10/07/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658123657 | CMS |
| Novo Nordisk AS | $129.89 | 10/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703542681 | CMS |
| Novo Nordisk Inc | $425.23 | 10/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706572721 | CMS |
| Novo Nordisk Inc | $850.00 | 10/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706572723 | CMS |
| Novo Nordisk Inc | $794.28 | 10/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706572725 | CMS |
| Novo Nordisk Inc | $6,885.00 | 10/05/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706574841 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,400.00 | 10/04/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700459601 | CMS |
| Novo Nordisk Inc | $340.00 | 10/04/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703540369 | CMS |
| Amarin Pharma Inc. | $55.00 | 10/03/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699226847 | CMS |
| Amarin Pharma Inc. | $137.50 | 10/03/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699226849 | CMS |
| Novo Nordisk AS | $359.34 | 10/03/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703542683 | CMS |
| Novo Nordisk AS | $78.64 | 10/03/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703542685 | CMS |
| Novo Nordisk AS | $258.60 | 10/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703544305 | CMS |
| Novo Nordisk Inc | $14.68 | 10/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 690067239 | CMS |
| Janssen Pharmaceuticals, Inc | $3,340.00 | 10/02/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658380223 | CMS |
| Janssen Pharmaceuticals, Inc | $3,340.00 | 10/02/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658380227 | CMS |
| Lilly USA, LLC | $10.83 | 10/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658106125 | CMS |
| Lilly USA, LLC | $1,288.32 | 10/02/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658123629 | CMS |
| Lilly USA, LLC | $3.25 | 10/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658123659 | CMS |
| Lilly USA, LLC | $54.14 | 10/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658123661 | CMS |
| Amgen Inc. | $8.51 | 10/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662953459 | CMS |
| Corcept Therapeutics | $13.92 | 10/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695483550 | CMS |
| SANOFI-AVENTIS U.S. LLC | $608.00 | 10/01/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694191327 | CMS |
| Novo Nordisk Inc | $425.23 | 09/30/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706573345 | CMS |
| Novo Nordisk Inc | $179.67 | 09/30/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706573347 | CMS |
| Novo Nordisk Inc | $850.00 | 09/30/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706573349 | CMS |
| Novo Nordisk Inc | $179.67 | 09/30/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706574861 | CMS |
| Novo Nordisk Inc | $425.23 | 09/30/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706574863 | CMS |
| Novo Nordisk Inc | $7,395.00 | 09/30/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706574865 | CMS |
| Amarin Pharma Inc. | $40.00 | 09/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699227971 | CMS |
| Amarin Pharma Inc. | $176.00 | 09/27/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699227983 | CMS |
| Lilly USA, LLC | $200.00 | 09/27/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658116353 | CMS |
| Janssen Pharmaceuticals, Inc | $1,372.74 | 09/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658380209 | CMS |
| Janssen Pharmaceuticals, Inc | $100.01 | 09/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658380213 | CMS |
| Lilly USA, LLC | $4.83 | 09/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658119465 | CMS |
| Janssen Pharmaceuticals, Inc | $700.32 | 09/25/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658380201 | CMS |
| Janssen Pharmaceuticals, Inc | $121.75 | 09/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658380205 | CMS |
| SANOFI-AVENTIS U.S. LLC | $608.00 | 09/25/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694166629 | CMS |
| Amgen Inc. | $2,500.00 | 09/24/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662953471 | CMS |
| Amgen Inc. | $417.00 | 09/24/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662953479 | CMS |
| AstraZeneca Pharmaceuticals LP | $4,300.00 | 09/24/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685981685 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $5.62 | 09/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700459677 | CMS |
| SANOFI-AVENTIS U.S. LLC | $103.52 | 09/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694127409 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $874,281.36 | 60 |
| PY2024 | Recipient | $2,478.46 | 8 |
| PY2024 | Principal investigator | $997,734.79 | 192 |
| PY2023 | Recipient | $3,696.79 | 17 |
| PY2023 | Principal investigator | $889,200.29 | 723 |
| PY2022 | Recipient | $3,111.75 | 8 |
| PY2022 | Principal investigator | $600,742.52 | 1,412 |
| PY2021 | Recipient | $826.30 | 1 |
| PY2021 | Principal investigator | $891,640.24 | 1,058 |
| PY2020 | Recipient | $9,878.95 | 10 |
| PY2020 | Principal investigator | $971,932.07 | 703 |
| PY2019 | Recipient | $1,447.12 | 11 |
| PY2019 | Principal investigator | $1,091,759.42 | 277 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
60 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $5,520.00 | 12/31/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism | No dispute reported | 06/30/2026 | 1202534403 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 12/17/2025 | Non-covered Recipient Entity Albany Med Health System-Endocrinology | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220696147 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 12/17/2025 | Non-covered Recipient Entity Albany Med Health System-Endocrinology | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220696149 |
| Principal investigator 1 | Senseonics, Incorporated | $125.00 | 12/04/2025 | Non-covered Recipient Entity AM DIABETES & ENDOCRINOLOGY | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249851821 |
| Principal investigator 1 | Senseonics, Incorporated | $312.50 | 12/04/2025 | Non-covered Recipient Entity AM DIABETES & ENDOCRINOLOGY | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249851823 |
| Principal investigator 1 | Senseonics, Incorporated | $1,126.56 | 12/04/2025 | Non-covered Recipient Entity AM DIABETES & ENDOCRINOLOGY | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249851825 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Albany Med Health System-Endocrinology | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220696139 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 12/01/2025 | Non-covered Recipient Entity Albany Med Health System-Endocrinology | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220696141 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 12/01/2025 | Non-covered Recipient Entity Albany Med Health System-Endocrinology | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220696143 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 12/01/2025 | Non-covered Recipient Entity Albany Med Health System-Endocrinology | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220696145 |
| Principal investigator 1 | ABBVIE INC. | $18,362.70 | 11/05/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202521969 |
| Principal investigator 1 | Novo Nordisk AS | $500.00 | 11/05/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | NN9535-4801 | No dispute reported | 06/30/2026 | 1213704066 |
| Principal investigator 1 | Novo Nordisk AS | $1,000.00 | 11/05/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | NN9535-4801 | No dispute reported | 06/30/2026 | 1213770377 |
| Principal investigator 1 | ABBVIE INC. | $5,718.60 | 10/09/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202513725 |
| Principal investigator 1 | Senseonics, Incorporated | $62.50 | 09/11/2025 | Non-covered Recipient Entity AM DIABETES & ENDOCRINOLOGY | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249851811 |
| Principal investigator 1 | Senseonics, Incorporated | $62.50 | 09/11/2025 | Non-covered Recipient Entity AM DIABETES & ENDOCRINOLOGY | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249851813 |
| Principal investigator 1 | Senseonics, Incorporated | $187.50 | 09/11/2025 | Non-covered Recipient Entity AM DIABETES & ENDOCRINOLOGY | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249851815 |
| Principal investigator 1 | Senseonics, Incorporated | $2,253.12 | 09/11/2025 | Non-covered Recipient Entity AM DIABETES & ENDOCRINOLOGY | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249851817 |
| Principal investigator 1 | Senseonics, Incorporated | $250.00 | 09/11/2025 | Non-covered Recipient Entity AM DIABETES & ENDOCRINOLOGY | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249851819 |
| Principal investigator 1 | ABBVIE INC. | $15,506.10 | 09/04/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202508682 |
| Principal investigator 1 | ABBVIE INC. | $12,553.65 | 08/06/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202502330 |
| Principal investigator 1 | Amgen Inc. | $21,726.14 | 07/28/2025 | Non-covered Recipient Entity ALBANY MEDICAL CENTER COMMUNITY DIVISION | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246638919 |
| Principal investigator 1 | Novo Nordisk AS | $2,195.28 | 07/21/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | NN9535-4801 | No dispute reported | 06/30/2026 | 1213821980 |
| Principal investigator 1 | Senseonics, Incorporated | $1,126.56 | 07/17/2025 | Non-covered Recipient Entity AM DIABETES & ENDOCRINOLOGY | Senseonics CTP-0039 | No dispute reported | 06/30/2026 | 1249851809 |
| Principal investigator 1 | ABBVIE INC. | $11,772.00 | 07/02/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202494163 |
| Principal investigator 1 | Eli Lilly and Company | $93,668.00 | 06/24/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULT PARTICIPANTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-1) | No dispute reported | 06/30/2026 | 1187875919 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $290.00 | 06/05/2025 | Covered Recipient Teaching Hospital ALBANY MEDICAL CENTER HOSPITAL | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | No dispute reported | 06/30/2026 | 1223263412 |
| Principal investigator 1 | ABBVIE INC. | $21,770.10 | 06/03/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202488461 |
| Principal investigator 1 | Senseonics, Incorporated | $2,253.12 | 05/15/2025 | Non-covered Recipient Entity AM DIABETES & ENDOCRINOLOGY | Senseonics CTP-0034 | No dispute reported | 06/30/2026 | 1249851807 |
| Principal investigator 1 | ABBVIE INC. | $15,376.50 | 05/07/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202483693 |
| Principal investigator 1 | Amgen Inc. | $5,498.75 | 04/22/2025 | Non-covered Recipient Entity ALBANY MEDICAL CENTER COMMUNITY DIVISION | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) | No dispute reported | 06/30/2026 | 1246638923 |
| Principal investigator 1 | ABBVIE INC. | $9,011.25 | 04/03/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202471351 |
| Principal investigator 1 | Novo Nordisk AS | $26,154.23 | 03/31/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | EX9924-4473 | No dispute reported | 06/30/2026 | 1213796723 |
| Principal investigator 1 | Eli Lilly and Company | $875.00 | 03/25/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187880497 |
| Principal investigator 1 | Senseonics, Incorporated | $2,253.12 | 03/13/2025 | Non-covered Recipient Entity AM DIABETES & ENDOCRINOLOGY | Senseonics CTP-0034 | No dispute reported | 06/30/2026 | 1249851805 |
| Principal investigator 1 | ABBVIE INC. | $12,353.85 | 03/07/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202459368 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $22,167.84 | 03/06/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190299637 |
| Principal investigator 1 | Senseonics, Incorporated | $1,176.56 | 02/27/2025 | Non-covered Recipient Entity AM DIABETES & ENDOCRINOLOGY | Senseonics CTP-0034 | No dispute reported | 06/30/2026 | 1249851803 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $580.00 | 02/27/2025 | Covered Recipient Teaching Hospital ALBANY MEDICAL CENTER HOSPITAL | PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | No dispute reported | 06/30/2026 | 1223263410 |
| Principal investigator 1 | Amgen Inc. | $4,672.40 | 02/25/2025 | Non-covered Recipient Entity ALBANY MEDICAL CENTER COMMUNITY DIVISION | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | No dispute reported | 06/30/2026 | 1246638925 |
| Principal investigator 1 | Novo Nordisk AS | $2,000.00 | 02/21/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | EX9924-4473 | No dispute reported | 06/30/2026 | 1213804886 |
| Principal investigator 1 | Eli Lilly and Company | $12,435.00 | 02/11/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1187874153 |
| Principal investigator 1 | Eli Lilly and Company | $135,385.00 | 02/11/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY | No dispute reported | 06/30/2026 | 1187876091 |
| Principal investigator 1 | ABBVIE INC. | $13,603.95 | 02/06/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202449583 |
| Principal investigator 1 | Eli Lilly and Company | $42,129.00 | 02/04/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187875619 |
| Principal investigator 1 | Eli Lilly and Company | $27,900.00 | 02/04/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | No dispute reported | 06/30/2026 | 1187877689 |
| Principal investigator 1 | Eli Lilly and Company | $780.98 | 01/31/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | No dispute reported | 06/30/2026 | 1187873609 |
| Principal investigator 1 | Eli Lilly and Company | $570.00 | 01/31/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR | No dispute reported | 06/30/2026 | 1187875917 |
| Principal investigator 1 | Eli Lilly and Company | $2,431.08 | 01/31/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY | No dispute reported | 06/30/2026 | 1187876093 |
| Principal investigator 1 | Senseonics, Incorporated | $2,253.12 | 01/30/2025 | Non-covered Recipient Entity AM DIABETES & ENDOCRINOLOGY | Senseonics CTP-0034 | No dispute reported | 06/30/2026 | 1249851801 |
| Principal investigator 1 | Amgen Inc. | $12,245.12 | 01/27/2025 | Non-covered Recipient Entity ALBANY MEDICAL CENTER COMMUNITY DIVISION | A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM | No dispute reported | 06/30/2026 | 1246638927 |
| Principal investigator 1 | Eli Lilly and Company | $1,945.58 | 01/27/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1187873125 |
| Principal investigator 1 | Eli Lilly and Company | $7,223.66 | 01/27/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187873607 |
| Principal investigator 1 | Eli Lilly and Company | $1,044.45 | 01/27/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187877693 |
| Principal investigator 1 | Eli Lilly and Company | $36,724.00 | 01/21/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE | No dispute reported | 06/30/2026 | 1187873229 |
| Principal investigator 1 | Eli Lilly and Company | $49,519.00 | 01/21/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187875617 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $315.41 | 01/15/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190310016 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $27,433.75 | 01/14/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190299633 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,390.40 | 01/14/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190299641 |
| Principal investigator 1 | Eli Lilly and Company | $174,866.00 | 01/07/2025 | Non-covered Recipient Entity ALBANY MEDICAL COLLEGE | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187877691 |